Clinically studied GHK-Cu & PDRN at an efficacious 2% — regenerative peptide results delivered through the skin.
GHK-Cu Peptide
Clinical Study
Saw Results
Formulated with peptides at concentrations that work. no fillers. no compromises.
GHK-Cu — Glycyl-L-Histidyl-L-Lysine·Copper(II) — is a naturally occurring tripeptide first isolated from human plasma in 1973. Present in the skin at birth, its concentration declines by over 60% between the ages of 20 & 60. With it goes the skin's capacity to repair itself.
PDRN — Poly-Deoxy-Ribo-Nucleotide — was identified in the 1980s by Italian researchers studying human placenta. What they found was a DNA fragment that speaks directly to skin cells, switching on the receptor pathway behind new collagen. As the body ages, that signal weakens — taking the skin’s repair response down with it.
At 2%, RHÉVA reaches the threshold shown in peer-reviewed studies to activate collagen synthesis, stimulate fibroblast production, & initiate the skin's own tissue repair cascade.
Not surface-level hydration — structural regeneration.
GHK · Cu²⁺
Glycyl-L-Histidyl-L-Lysine · Copper(II) Complex
Tripeptide-copper complex. MW 340.38 g/mol. Naturally present in human plasma, saliva, and urine. Concentration declines significantly with age.
— clinical observations —
12-week observational study. 32 participants aged 21-65 receiving RHÉVA GHK-Cu Serum twice daily. No consumers were paid. Results self-reported and dermatologist-corroborated.
Week 1-2
Skin feels replenished, softer and visibly smoother to the touch.
Week 4-6
A more refined appearance emerges as tone and surface irregularities begin to settle.
Week 8-10
The complexion appears firmer, brighter and increasingly resilient day by day.
Week 12
A visibly renewed complexion with improved texture, hydration and overall skin quality.
